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ABSTRACT 
 
BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia but the functional 
implications of BIRC3 mutations are largely unexplored. Also, little is known about the prognostic 
impact of BIRC3 mutations in chronic lymphocytic leukemia cohorts homogeneously treated with 
first line fludarabine, cyclophosphamide, and rituximab. By immunoblotting analysis, we showed 
that the non-canonical NF-κB pathway is active in BIRC3 mutated cell lines and in primary chronic 
lymphocytic leukemia samples, as documented by the stabilization of MAP3K14 and by the nuclear 
localization of p52. In addition, BIRC3 mutated primary chronic lymphocytic leukemia cells are 
less sensitive to fludarabine.  In order to confirm in patients that BIRC3 mutations confer resistance 
to fludarabine-based chemoimmunotherapy, a retrospective multicenter cohort of 287 untreated 
patients receiving first-line fludarabine, cyclophosphamide, and rituximab was analyzed by targeted 
next generation sequencing of 24 recurrently mutated genes in chronic lymphocytic leukemia. By 
univariate analysis adjusted for multiple comparisons BIRC3 mutations identify a poor prognostic 
subgroup of patients failing fludarabine, cyclophosphamide, and rituximab (median progression free 
survival: 2.2 years, p < 0.001) similar to cases harboring TP53 mutations (median progression free 
survival: 2.6 years, p < 0.0001). BIRC3 mutations maintained an independent association with an 
increased risk of progression with a hazard ratio of 2.8 (95% confidence interval 1.4-5.6, p = 0.004) 
in multivariate analysis adjusted for TP53 mutation, 17p deletion and IGHV mutation status. If 
validated, BIRC3 mutations may be used as a new molecular predictor to select high-risk patients 
for novel frontline therapeutic approaches. 
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INTRODUCTION 
 
Nuclear factor-κB (NF-κB) signaling is a key component of chronic lymphocytic leukemia 
(CLL) development and evolution.1 Two NF-κB pathways exist namely, canonical and non-
canonical.2 The former is triggered by the B-cell receptor (BCR) signaling via the Bruton’s tyrosine 
kinase (BTK), while the latter is activated by members of the tumor necrosis factor (TNF) cytokine 
family.3 Upon receptor binding, the TRAF3/MAP3K14-TRAF2/BIRC3 negative regulatory 
complex of non-canonical NF-κB signaling is disrupted, MAP3K14 (also known as NIK), the 
central activating kinase of the pathway, is released and activated to induce the phosphorylation and 
proteasomal processing of p100, thereby leading to the formation of p52-containing NF-κB dimers. 
The p52 protein dimerizes with RelB to translocate into the nucleus, where it regulates gene 
transcription. BIRC3 is a negative regulator of non-canonical NF-κB. Physiologically, BIRC3 (also 
known as cIAP2) catalyzes MAP3K14 protein ubiquitination in a manner that is dependent on the 
E3 ubiquitinine ligase activity of its C-terminal RING domain. MAP3K14 ubiquitination results 
into its proteasomal degradation.4 
B-cell neoplasia often pirates signaling pathways by molecular lesions to promote survival 
and proliferation. Though according to bioinformatics criteria BIRC3 is one of the candidate driver 
genes of CLL, the functional implications of BIRC3 mutations are partially unexplored.5-7 Also, 
little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously 
treated with first line fludarabine, cyclophosphamide, and rituximab (FCR).7  
FCR is the most effective chemoimmunotherapy regimen for the management of CLL in 
young and fit patients devoid of TP53 disruption.8 Survival after FCR, however, is variable, and is 
affected by the molecular characteristics of the CLL clone.9 Deletion of 17p and TP53 mutations 
capture most, but not all patients who are refractory to chemo-immunotherapy, which prompts the 
identification of additional biomarkers associated with early failure of FCR.10-12  
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METHODS 
 
Functional studies 
The human CLL cell line MEC1, the splenic marginal zone lymphoma (SMZL) cell lines 
SSK41 and VL51, the mantle cell lymphoma (MCL) cell lines MAVER-1, Z-138 and JEKO-1, the 
human HEK-293T cell line, as well as primary CLL cells were used in functional experiments. The 
entire non-canonical NF-κB pathway was assessed by Western blot. Quantitative real-time PCR 
(qRT-PCR) was utilized to analyze the non-canonical NF-κB signature. Primary CLL were exposed 
to fludarabine and venetoclax for 24-48 hours and apoptosis measured using the eBioscience 
Annexin V Apoptosis Detection Kit APC (ThermoFisher). Details are supplied in the 
Supplementary Methods. 
 
Cancer personalized profiling by deep sequencing (CAPP-seq) 
A retrospective multicenter cohort of 287 untreated CLL receiving first-line therapy with 
FCR was analyzed for mutations, including 173 patients derived from a previously published 
multicenter clinical series and 114 new patients not included in our previous report.10 The study was 
approved by the Ethical Committee of the Ospedale Maggiore della Carità di Novara associated 
with the Amedeo Avogadro University of Eastern Piedmont (study number CE 67/14). Further 
information is supplied in the Supplementary Methods. A targeted resequencing gene panel was 
designed to include: i) coding exons plus splice site of 24 genes known to be implicated in CLL 
pathogenesis and/or prognosis; ii) 3’UTR of NOTCH1; and iii) enhancer and promoter region of 
PAX5 (size of the target region: 66627bp) (Table S1).6,7 The next generation sequencing (NGS) 
libraries for genomic DNA (gDNA) were constructed using the KAPA Library Preparation Kit 
(Kapa Biosystems) and NGS libraries for RNA were constructed using RNA Hyper Kit (Roche). 
Multiplexed libraries (n = 10 per run) were sequenced using 300-bp paired-end runs on a MiSeq 
sequencer (Illumina) to obtain a coverage of at least 2000x in >90% of the target region (66627bp) 
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in 80% of cases (Table S2). A robust and previously validated bioinformatics pipeline was used for 
variant calling (Supplemental Appendix). 
 
Statistical analysis 
Progression free survival (PFS) was the primary endpoint. Survival analysis was performed 
by Kaplan-Meier method and compared between strata using the Log-rank test. To account for 
multiple testing, adjusted p-values were calculated using the Bonferroni correction. The adjusted 
association between exposure variables and PFS was estimated by Cox regression. Internal 
validation of the multivariate analysis was performed using a bootstrap approach. Statistical 
significance was defined as p value < 0.05 (Supplemental Appendix). 
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RESULTS 
 
BIRC3 mutations associate with activation of non-canonical NF-κB signaling   
In order to comprehensively map unique BIRC3 mutations in CLL, we compiled somatically 
confirmed variants identified in the current CLL study cohort with those identified in previous 
studies13 or listed in public CLL mutation catalogues (Figure 1 A). Virtually all BIRC3 mutations 
were represented by frameshift or stop codons clustering in two hotspot regions comprised between 
amino acid 367-438 and amino acid 537-564. BIRC3 variants were predicted to generate aberrant 
truncated transcripts causing the elimination or truncation of the C-terminal RING domain of the 
BIRC3 protein. The RING domain of BIRC3 harbors the E3 ubiquitin ligase activity that is 
essential for proteasomal degradation of MAP3K14, the central activating kinase of the non-
canonical NF-κB
 
signaling. This observation points to non-canonical NF-κB activation through 
MAP3K14 stabilization as the predicted functional consequence of BIRC3 mutations in CLL.   
The non-canonical NF-κB
 
signaling was profiled by immunoblotting in B-cell tumor cell 
lines and primary CLL cells with different genetic make-up in the non-canonical NF-κB pathway to 
verify whether BIRC3 mutations lead to constitutive non-canonical NF-κB activation. Additional 
genetic features of the above mentioned cell lines and primary CLL cells are shown in Table S3.  In 
the VL51 SMZL cell line and in the MEC1 CLL cell lines, both harboring endogenous truncating 
mutations of the BIRC3 gene, non-canonical NF-κB
 
signaling was constitutively active, as 
documented by the stabilization of MAP3K14, phosphorylation of NF-κB2, its processing from 
p100 to p52, as well as nuclear localization of p52 (Figure 1 B-D). Consistent with the biochemical 
clues of non-canonical NF-κB activation, the gene expression signature of the VL51 and MEC1 cell 
lines was significantly enriched of non-canonical NF-κB target genes (Figure 1 E-F). Non-canonical 
NF-κB
 
signaling in BIRC3 mutated cells was consistent with that of MCL cell lines known to 
harbor a disrupted TRAF3/MAP3K14-TRAF2/BIRC3 negative regulatory complex by loss of 
TRAF3 or TRAF2.14 As BIRC3 mutated cell lines, also primary CLL samples harboring 
inactivating mutations of BIRC3 showed stabilization of MAP3K14 and NF-κB2 processing from 
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p100 to p52 (Figure 1 C), thus confirming that non-canonical NF-κB activation is also a feature of 
primary cells harboring BIRC3 variants. MAP3K14 stabilization is largely associated with BIRC3 
mutations. Indeed 7/7 cases harboring non canonical NF-κB genetic lesions showed either a strong 
or a slight MAP3K14 band, while, conversely, only one out of 5 cases lacking non canonical NF-
κB lesion had MAP3K14 expression (p by Fisher’s exact test 0.01). 
MAP3K14 was genetically targeted by shRNA to test whether BIRC3 mutated cells are 
addicted of its stabilization. Compared to non-targeting shRNA, the most efficient anti MAP3K14 
shRNA-D resulted in a partial silencing of MAP3K14 and in a decreased NF-κB2 processing from 
p100 to p52. This translated into a reduced cell viability of the BIRC3 mutated VL51 cell line 
transduced with shRNA-D. This observation indicates that MAP3K14 stabilization is a 
vulnerability of BIRC3 mutated cells (Figure 2). In order to test the contribution of BTK to non-
canonical NF-κB signaling when it is activated through BIRC3 mutations, BIRC3 mutated cell lines, 
as well as cell lines harboring a disrupted or competent TRAF3/MAP3K14-TRAF2/BIRC3 negative 
regulatory complex were treated with ibrutinib at different dosage and non-canonical NF-κB 
signaling activation probed by immunoblotting of the NF-κB2 processing from p100 to p52. 
Processing from p100 to p52 was unaffected by ibrutinib treatment in cell lines harboring BIRC3 
mutations (Figure 3) or a disrupted TRAF3/MAP3K14-TRAF2/BIRC3 negative regulatory complex 
consistent with the notion that BIRC3 mutations activate non-canonical NF-κB
 
by
 
bypassing BTK 
blockade by ibrutinib.14 
 
BIRC3 mutations confer resistance to fludarabine in primary CLL cells  
We performed in vitro pharmacological studies on primary CLL cells to verify the 
vulnerabilities of BIRC3 mutated cells. CLL cells purified from patients carrying BIRC3 mutations 
were treated with increasing doses of fludarabine. Drug-induced apoptosis was compared to 
samples harboring TP53 mutations, which represent a control for fludarabine resistance. CLL cells 
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devoid of genetic lesions on either BIRC3 or TP53 were adopted as a control cohort for fludarabine 
sensitivity. Molecular characteristic of the ex-vivo CLL cells are listed in Table S4. 
BIRC3 mutated cells showed a delayed fludarabine-induced cell death, as no response was 
observed after 24-hour treatment, at variance with TP53 and BIRC3 wild type samples. At this time 
point, cell viability curves of BIRC3 mutated samples were almost completely overlapping with that 
of TP53 disrupted samples, which are known to be fludarabine resistant (Figure 4 A). At 48 hours, 
BIRC3 mutated cells had viability that was lower than that of TP53 mutated samples, but higher 
than that of TP53 and BIRC3 wild type samples (Figure 4 B).  
In order to assess whether BIRC3 mutations interfere with apoptosis, primary CLL cells 
were treated with venetoclax. Venetoclax treatment resulted in similar reduction of cell viability in 
BIRC3 mutated cells, TP53 mutated cells and BIRC3/TP53 wild type cells (Figure 4 C,D). Such 
divergent sensitivity to fludarabine and venetoclax of BIRC3 mutated CLL cells indirectly suggests 
that BIRC3 mutations likely affect the upstream DNA damage response pathway rather than the 
downstream apoptosis among mechanisms of cell death induction. 
 
Patients harboring BIRC3 mutations are at risk of failing FCR 
 In order to confirm in vivo in patients that BIRC3 mutations confer resistance to fludarabine-
based chemoimmunotherapy, we correlated the BIRC3 mutation status with PFS in FCR treated 
CLL. Mutational profiling was performed in 287 patients who received first line FCR. The baseline 
features of the study cohort were consistent with progressive, previously untreated CLL (Table 1).  
The median follow-up was 6.8 years, with a median PFS and OS of 4.6 and 11.7 years, respectively 
(Table 1) consistent with clinical trial cohorts.15 As expected, SF3B1 and NOTCH1were the most 
frequently mutated genes identified in 13.9% and in 13.6% of patients respectively, followed by 
TP53 in 9.4% and ATM in 6.9% of patients. BIRC3 was mutated in 3.1% of patients, reflecting the 
data reported in previous studies.6,7,13 Overall, 154/287 (53.6%) cases harbored at least one non-
synonymous somatic mutation in one of the 24 CLL genes included in our panel (range: 1-5 
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mutation per patient), which is consistent with the typical mutational spectrum of CLL requiring 
first line treatment (Figure 5; Table S5). 6,7,16 
By univariate analysis adjusted for multiple comparisons, among the genes analyzed in our 
panel, only TP53 mutations (median PFS of 2.6 years; p < 0.0001) and BIRC3 mutations (median 
PFS of 2.2 years; p < 0.001) (Figure 6 A) associated with significantly shorter PFS (Table 2). The 
PFS after FCR of BIRC3 mutated patients was similar to that of cases harboring TP53 disruption 
(Figure 6 B). Consistently, BIRC3 mutated patients had a lower likelihood of achieving complete 
response (22.2%) at the end of FCR compared to BIRC3 wild type cases (76.7%; p=0.001). Well-
known molecular prognostic biomarkers of CLL, such as unmutated IGHV gene status and 17p 
deletion also associated with a significantly shorter PFS, supporting the representativeness of the 
study cohort (Table 2). By multivariate analysis including variables showing a multiplicity adjusted 
significant association with PFS, BIRC3 mutations maintained an independent association with 
PFS, with a HR of 2.8 (95% C.I. 1.4-5.6, p = 0.004) (Table 2). 
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DISCUSSION 
 
The results of this study provide the evidence that: i) BIRC3 mutations associate with 
activation of the non-canonical NF-κB pathway and with resistance to fludarabine in vitro; and that 
ii) BIRC3 mutated patients fail FCR chemoimmunotherapy analogous to cases harboring TP53 
disruption. 
The mere presence of somatic mutations is insufficient to implicate a gene in cancer. Cancer 
geneticists and bioinformaticians differentiate “passengers” events, likely being randomly acquired, 
to distinguish them from mutations targeting candidate “cancer driver” genes, likely implicated in 
the tumor biology, according to a statistical definition. Any given gene is labeled as candidate 
“cancer driver” if it harbors somatic point mutations at a statistically significant rate or pattern in 
cancer samples. In CLL, more than 40 genes fulfill the statistical definition of candidate “cancer 
driver”, including BIRC3, but few of them are biologically validated (i.e. SF3B1, NOTCH1, TP53, 
ATM, FBXW7).6,7,17-20 The BIRC3 (Baculoviral IAP Repeat Containing 3) gene codes for a protein 
that ubiquitinates and negatively regulates the central activating kinase of the non-canonical NF-κB 
pathway, namely MAP3K14 (also known as NIK).21,22 In lymphoid malignancies, the NF-κB 
pathway is a pivotal and positive mediator of cell proliferation and survival.5,23,24 In CLL, BIRC3 
mutations are absent in monoclonal B-cell lymphocytosis (MBL) patients, are rare at the time of 
diagnosis (3-4%), but are detectable in approximately 25% of fludarabine refractory patients.13 In 
this study, we verified the biological consequences of  BIRC3 mutations by showing that they 
associate with activation of the non-canonical NF-κB pathway, that BIRC3 mutated lymphoid cells 
are addicted of non-canonical NF-κB pathway, and that BIRC3 mutated CLL are resistant to 
fludarabine both in vitro and in patients. It still remains to be clarified whether NF-κB activation is 
the only molecular pathway that causes chemo-refractoriness in BIRC3 mutated CLL or whether 
other mechanisms are also involved.24-29  
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The introduction of FCR has represented a breakthrough in the management of young and fit 
CLL patients with an improvement in both PFS and OS compared to previous regiments. In both 
clinical trials and real life cohorts,10-12 IGHV mutation status and TP53 disruption sorted out as 
strong predictors of poor response to FCR. However, these molecular biomarkers do not fully 
capture all high-risk patients destined to relapse. We propose BIRC3 mutations as a new biomarker 
for the identification of high-risk patients failing FCR similarly to cases harboring TP53 disruption. 
If validated in independent series, BIRC3 mutations may turn out as a new molecular predictor of 
FCR resistance to be use for selecting patients to be treated with novel targeted agents.  
Non-canonical NF-κB activation by BIRC3 mutations by-pass the block of BTK by 
ibrutinib. Consistently, NF-κB activation and cell survival is unaffected by ibrutinib in both CLL 
cells (our study) and mantle cell lymphoma cells.14 If this pre-clinical evidence will be validated in 
ibrutinib-treated patients, BIRC3 mutations may translate in a biomarker also for informing 
selection of novel agents.  
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Table 1. Clinical data of FCR-treated CLL patients accordig to BIRC3 mutational status   
     
Characteristics Total Number of patients (%) BIRC3 mutated patients (%) BIRC3 wild type patients (%) 
Male 
N=287 
198 (69.0%) 
5 (55.6%) 193 (69.4%) 
Female 
89 (31.0%) 
4 (44.4) 85 (30.6%) 
Binet A 
N=287 
33 (11.5%) 
1 (11.1%) 32 (11.5%) 
Binet B-C 
254 (88.5%) 
8 (88.9%) 246 (88.5%) 
IGHV mutated 
N=280 
100 (35.7%) 
0 (0%) 100 (36.0%) 
IGHV unmutated 
180 (64.3%) 
9 (100%) 171 (61.5%) 
17p deletion 
N=274 
13 (4.7%) 
0 (0%) 13 (4.7%) 
No 17p deletion 
261 (95.3%) 
9 (100%) 252 (90.6%) 
11q deletion 
N=273 
47 (17.2%) 
5 (55.6%) 42 (15.1%) 
No 11q deletion 
226 (82.8%) 
4 (44.4) 222 (79.9%) 
13q deletion 
N=273 
111 (40.7%) 
3 (33.3%) 108 (38.8%) 
No 13q deletion 
162 (50.3%) 
6 (66.6%) 156 (56.1%) 
Trisomy 12 
N=272 
50 (18.4%) 
4 (44.4%) 46 (16.5%) 
No Trisomy 12 
222 (81.6%) 
5 (55.6%) 217 (78.1%) 
  
    
 
 
Median Follow-up (years) 
  6.8 
 
 
Median PFS  (years)  4.6   
PFS % (7-years)   31.0%   
Median OS (years)  11.7  
 
OS % (7-years)   75.5%  
 
PFS, progression free survival; OS, overall survival; IGHV, immunoglobulin heavy variable gene.  
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Table 2. Univariate and multivariate analysis of PFS 
 
Univariate analysis     Multivariate analysis   Internal bootstrapping validation 
                
Characteristics 
7-y PFS 
(%) 
Median 
PFS (y) 
95% CI P  P*   HR LCI UCI P   HR LCI UCI 
Bootstrapping 
selection (%) 
Binet A 40.3% 4.5 2.4-6.6 
0.356 - 
 - 
- - 
- 
 - - - 
- 
Binet B-C 30.0% 4.6 3.8-5.4  - 
- - 
 - - - 
IGHV mutated 49.3% 6.5 
3.8-9.2 
<0.001 0.003 
  - 
- - 
0.001 
  - - - 
98.8% 
IGHV unmutated 23.0% 3.9 
3.5-4.4 
  1.8 
1.3 2.6 
  1.9 1.3 2.7 
No 11q deletion 33.4% 5.0 
4.2-5.9 
0.025 0.700 
 - 
- - 
- 
 - - - 
- 
11q deletion 13.9% 3.6 
2.4-4.9 
 - 
- - 
 - - - 
No 17p deletion 33.0% 4.8 
4.1-5.6 
<0.0001 <0.0001 
  - - - 
<0.0001 
  - - - 
99.5% 
17p deletion nr 1.1 
0-2.6 
  4.0 
2.2 7.5 
  4.9 2.5 9.8 
TP53 Wild type 33.8% 5.4 
4.3-5.8 
<0.0001 <0.001 
 - 
- - 
0.030 
 - 
- - 
73.3% 
TP53 Mutated nr 2.8 
2.0-3.5 
 1.7 
1.1 2.8 
 1.8 1.1 3 
BIRC3 Wild type 32.2% 4.8 
4.1-5.6 
<0.001 0.005 
  - 
- - 
0.004 
  - - - 
91.1% 
BIRC3 Mutated nr 2.2 
0.9-3.5 
  2.8 
1.4 5.6 
  3.4 1.6 7.3 
EGR2Wild type 31.5% 4.7 
3.9-5.4 
0.015 0.420 
 - 
- - 
- 
 - - - 
- 
EGR2Mutated nr 1.5 
0-3.8 
 - 
- - 
 - - - 
ATM Wild type 32.5% 4.8 
4.1-5.6 
0.029 0.812 
  - 
- - 
- 
  - - - 
- 
ATM Mutated nr 3.2 
2.4-4.1 
  - 
- - 
  - - - 
P, P-value; P*, Bonferroni correction; PFS, progression free survival; CI, confidence interval; HR, hazard ratio; LCI, lower confidence interval; UCI, upper confidence interval; 
IGHV, immunoglobulin heavy variable gene; nr, not reached 
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FIGURE LEGENDS 
 
Figure 1: Non-canonical NF-κB pathway is active in BIRC3 mutated CLL cell lines and 
primary samples. (A) Disposition of BIRC3 mutations across the protein. The mutations identified 
by Landau et al.6, Puente et al.7 and from public CLL mutation catalogue (COSMIC v85) are 
plotted in grey. Individual BIRC3 mutations identified in the current studied cohort and in our 
previous study13 are plotted in red. (B) Western blot analysis of BIRC3 protein expression and NF-
κB2 activation and processing in the SMZL cell lines SSK41, VL51 and in the CLL cell line MEC1, 
carrying wild-type or disrupted BIRC3. The MAVER-1 and Z-138 cell lines were used as positive 
controls of non-canonical NF-κB activation, harboring genetic activation of non-canonical NF-kB 
signaling. The JEKO-1 and HEK 293T cell lines were used as negative controls for non-canonical 
NF-κB signalling. α-actin was used as a loading control. Color codes indicate the gene status in 
each cell lines. The aberrant BIRC3 band expressed in MEC1 and VL51 cell lines correspond in 
size to the predicted BIRC3-truncated protein, encoded by the mutant allele. (C) Western blot 
analysis showing BIRC3 expression and NF-kB2 processing in purified primary tumor cells from 5 
CLL and SMZL patients carrying wild-type or disrupted BIRC3. Color codes indicate the gene 
status in each cell lines. The aberrant BIRC3 bands in patients 09321, 14462 and 12603 correspond 
in size to the predicted BIRC3-truncated protein encoded by the mutant allele. α-actin was used as a 
loading control. (D) Western blot of whole cell extract, cytoplasmic or nuclear fractions of the 
SMZL and CLL cell lines probed for the NF-κB2 subunits p100 and p52. The MAVER-1 and Z-138 
cell lines served as positive controls while the JEKO-1 and HEK 293T cell lines were used as 
negative controls. ß-tubulin and BRG1 served as controls for the purity of the cytoplasmic and 
nuclear fractionations, respectively. (E) GSEA enrichment score and distribution of non-canonical 
NF-κB target genes along the rank of transcripts differentially expressed in the SMZL cell lines 
SSK41, VL51 and in the CLL cell line MEC1. The JEKO-1 cell line was used as negative control. 
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(F) Validation of non-canonical NF-κB target genes expression in the same SMZL and CLL cell 
lines as determined by quantitative real-time RT-PCR. Changes of genes expression were 
normalized to GAPDH expression; relative quantities were log2 normalized to control samples 
(MCL cell line JEKO-1). 
 
Figure 2: Knockdown of MAP3K14 by RNA interference in VL51 cells. (A) Western blot 
analysis for MAP3K14 expression and for NF-κB2 processing of p100 to p52. (B) VL51 cells 
viability assessed by trypan blue after transduction with lentiviral vectors expressing the 
shRNAD_MAP3K14 (in red), a scrambled shRNA (in blu), and in non transfected cells (in green). 
 
Figure 3: Non-canonical NF-κB pathway is not switched off by ibrutinib in BIRC3 mutated 
cell lines. Western blot showing p100/p52 expression in (A) MEC1 and (B) VL51 cell lines that 
harbors BIRC3 mutations. (C) MAVER-1 and (D) Z-138 cell lines, known to be affected by non-
canonical NF-κB pathway gene mutations and resistant to ibrutinib were used as positive controls. 
(E) JEKO-1 cell line, known to be devoid of NF-κB pathway gene mutations and sensitive to 
ibrutinib was used as negative control.  All cell lines were treated with different concentrations of 
ibrutinib for 72 and 96 hours. 
 
Figure 4: Responses of primary cells lines to fludarabine and venetoclax. Viability of BIRC3 
mutated  (n = 6 patients, red line), TP53 mutated (n =  8 patients, black line) and wild type (n = 7 
patients, blue line) primary CLL cells treated with different concentrations of fludarabine for (A) 24 
hours and (B) 48 hours and of venetoclax for (C) 24 hours and (D) 48 hours The pairwise p values 
have been listed in the tables below the respective figures. M, mutated; WT, wild type; NT, not 
treated.  
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Figure 5. Mutational profile of the FCR-treated cohort. Case-level mutational profiles of 287 
patients FCR-treated patients. Each column represents one tumor sample, each row represents one 
gene. The fraction of tumors with mutations in each gene is plotted on the right. The number and 
type of mutations in each patient is plotted above the heat map. Mutations are highlighted in red. 
IGHV mutational status, 17p deletion and 11q deletion are plotted in the bottom of the heatmap. 
 
Figure 6. Kaplan-Meier estimates of progression free survival in BIRC3 mutated patients. (A) 
Cases harboring BIRC3 mutations are represented by the red line. Cases wild type for this gene are 
represented by the blue line. (B) Cases harboring BIRC3 mutations are represented by the red line. 
Cases harboring TP53 disruption (including TP53 mutation and/or 17p deletion) are represented by 
the yellow line. Patients devoid of BIRC3 mutation and TP53 disruption are represented by the blue 
line. The Log-rank statistics p values are indicated adjacent curves. 
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SUPPLEMENTARY METHODS 
 
 
Cell studies 
The human CLL cell line MEC1, the SMZL cell lines SSK41, VL51, and the MCL cell lines MAVER-1, Z-138 and 
JEKO-1 were cultured under standard conditions in RPMI-1640 with L-glutamine supplemented with 10% fetal calf 
serum, 100 U/ml penicillin and 100 U/ml streptomycin (Sigma Aldrich). Human HEK-293T cells were maintained in 
Iscove’s Modified Dulbecco Medium (IMDM) supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 U/ml 
streptomycin and 2mM L-glutamine (Sigma Aldrich) under identical conditions.  
Three primary cells samples known to harbor heterozygous inactivating mutations of BIRC3 were included in the 
experiments. Two BIRC3 wild type cases were used as controls. 
 
Western blot analysis 
The entire non-canonical NF-κB pathway was assessed using the following specific primary antibodies: anti-BIRC3 (Cell 
Signaling, #3130), anti-TRAF2 (Cell Signaling, #4712), anti-TRAF3 (Cell Signaling, #4729), anti-MAP3K14 (Cell 
Signaling, #4994), anti-Phospho-NF-κB2 p100 (Cell Signaling, #4810), anti-NF-κB2 p100/p52 (Cell Signaling, #4882). 
Anti-b-actin (Sigma Aldrich, #A2066) was used as loading control. The Qproteome Nuclear Protein Kit (Qiagen) was 
used according to the manufacturer’s instructions to isolate nuclear proteins from cells. Anti-β-tubulin (Sigma Aldrich, 
#T5201) and anti-BRG1 (G-7) (Santa Cruz Biotechnology, #17796) were used as controls for the purity of the cytoplasmic 
and nuclear fractions, respectively. Horseradish peroxidase-conjugated goat anti-mouse (LI-COR, #926-80010) or anti-
rabbit (LI-COR, #926-80011) antibodies were used to highlight binding by enhanced chemiluminescence with the Clarity 
Western ECL Substrate (Biorad). Image acquisition and densitometric analyses were performed using the Molecular 
Imager Gel Doc XR System and the Quantity One software (Biorad). 
 
RNA extraction and gene expression profiling 
Total RNA was extracted from exponentially growing cell lines by TRIzol reagent (Life Technologies), and retro-
transcribed using the Reverse Transcription Kit (Applied Biosystems). Quantitative real-time PCR (qRT-PCR) was 
conducted with the Step One Plus apparatus (Step One software 2.0; Applied Biosystems) using commercially available 
TaqMan Gene expression assays (TNFAIP3: Hs00234713_m1; NFKB2: Hs00174517_m1; NFKBIA: Hs00153283_m1; 
NFKBIE: Hs00234431_m1; PLEK: Hs00950975_m1; WNT10: Hs00228741_m1; IL2RG: Hs00953624_m1; RELB: 
Hs00232389_m1; MALT1: Hs01120052_m1) (BIRC3: Hs00985031_g1) (Life Technologies). Reactions were done in 
triplicate from the same cDNA (technical replicates). The comparative CT method (ΔΔCT) was used to calculate relative 
expression levels of the gene under analysis, using GAPDH (Hs03929097_g1) as internal references.  
 
Knockdown of MAP3K14 by RNA interference  
Lentiviruses expressing 3 short hairpin RNAs (shRNAs) targeting MAP3K14, as well as the scrambled shRNA, were 
produced and cloned into the BamHI/HindIII cloning sites of the pGFP-C-shLenti vectors (OriGene Technologies). 
Within the 5’-LTR and 3’-LTR regions, each pGFP-C-shLenti vector contains an shRNA expression cassette driven by 
an U6 promoter, a puromycin resistance marker driven by a SV40 promoter and a GFP driven by a CMV promoter. The 
shRNA expression cassette consists of 29 bp target-gene-specific sequence, a 7 bp loop, and another 29 bp reverse 
complementary sequence, followed by a TTTTTT termination sequence. The HEK293T cell line was co-transfected with 
expression (3 different pGFP-C-MAP3K14-shLenti or pGFP-C-non-effective-shLenti) vectors and adjuvant vectors 
(pMDL, REV and VSV-G). Fluorescence microscope was utilized to check the expression of the GFP in the transfected 
HEK293T cell line. After virus titration, the VL51 cell line was infected with lentiviruses harboring the shRNAs against 
MAP3K14 and the scrambled through a spinoculation protocol. After four days, infected cells were monitored by flow 
cytometry for the expression of the GFP and were selected by puromycin (1.5 µg/mL).  
 
Inhibitor studies 
Cells were put under starvation in RPMI 0.1% FBS 24h before treatment. Then they were seeded at 8000 cells per well 
in a 96-well U-bottom plate and treated with 1 µM, 5 µM and 10 µM of Ibrutinib (PCI-32765, Selleckchem) or vehicle 
(DMSO). Relative growth was determined by a Cell-Titer Glo (CTG) Luminescent Cell Viability Assay (Promega) 72h 
and 96h after treatment, according to the manufacturer’s instructions and luminescence was quantified using a Victor X 
(PerkinElmer) multilabel reader. Treatments were done in triplicate (biological replicates). 
 
In vitro drug responses in primary CLL cells 
Leukemic cells were purified using Ficoll-Hypaque (Sigma Aldrich) from peripheral blood (PB) of CLL patients. Staining 
with CD19 and CD5 confirmed that in all samples leukemic cells were >90%. Patients were then divided into BIRC3 
mutated (MUT) or wild-type (WT). TP53 mutated samples (and BIRC3 WT) were selected as positive control (i.e., cells 
intrinsically resistant to therapies). Cells were cultured in RPMI 10% FCS (200 µl, all reagents from Sigma) at a density 
of 5x106/ml and both dose- and time-dependent responses were analyzed. Specifically, CLL cells were exposed to 
fludarabine) for 24-48 hours. Fludarabine was used at 1-5-10-25 µM and venetoclax at 5-10-50-100-500-2000 nM. 
 
Apoptosis assay 
Drug-induced apoptosis was measured using the eBioscience™ Annexin V Apoptosis Detection Kit APC (ThermoFisher) 
following the manufacturer’s instruction. Data were acquired using a FACSCanto II cytofluorimeter (BD Biosciences) 
and processed with DIVA v6.1.3 and FlowJo Version 9.01 (TreeStar).  
 
FCR treated patients 
The study was designed as a retrospective observational analysis from a multicenter cohort of 287 (275 with complete 
clinical and molecular data) untreated CLL receiving first-line therapy with FCR in 17 different hematological centers. 
The following biological material was collected: i) 280 tumor genomic DNA (gDNA) and 7 tumor RNA isolated from 
peripheral blood (PB) before treatment start; and ii) paired germline gDNA from saliva from 14 cases. Normal gDNA 
from 22 healthy donors was also used to set the experimental background of the deep next generation sequencing (NGS) 
approach. Tumor and normal gDNA was extracted according to standard procedures1.Tumor RNA was extracted 
according to the TRIzol Reagent protocol (Ambion Life Technologies). The clinical database was updated in April 2018. 
Patients provided informed consent in accordance with local Institutional Review Board requirements and the Declaration 
of Helsinki. The study was approved by the Ethical Committee of the Ospedale Maggiore della Carità di Novara 
associated with the Amedeo Avogadro University of Eastern Piedmont (study number CE 67/14). 
 
Cancer personalized profiling by deep sequencing (CAPP-seq) 
A targeted resequencing gene panel 2 was designed to include: i) coding exons plus splice site of 24 CLL genes known to 
be implicated in CLL pathogenesis and/or prognosis; ii) 3’UTR of NOTCH1; and iii) enhancer and promoter region of 
PAX5 3,4 (size of the target region: 66627bp). Tumor and germline gDNA were quantified using the Quant-iTTM PicoGreen 
dsDNA Assay kit (ThermoFisher Scientific) and 400 ng were sheared through sonication (Covaris M220 focused-
ultrasonicator) before library construction to obtain 200-bp fragments. The size of the DNA fragments was checked using 
the Bioanalyzer (Agilent Technologies). The NGS libraries for gDNA were constructed using the KAPA Library 
Preparation Kit (Kapa Biosystems) and NGS libraries for RNA were constructed using RNA Hyper Kit (Roche) following 
the manufacturer’s instructions. Hybrid selection was performed with the custom SeqCap EZ Choice Library (Roche 
NimbleGen). Multiplexed libraries (n = 10 per run) were sequenced using 300-bp paired-end runs on a MiSeq sequencer 
(Illumina). 
 
Bioinformatic pipeline for variant calling after CAPP-seq 
Initially, FASTQ sequencing reads were deduped. We deduped FASTQ sequencing reads from gDNA by utilizing the 
FastUniq v1.1 software, that collapses as duplicate reads only those fragments (read pairs) with 100% sequence identity 
that also share genomic coordinates. The same approach was also used to dedupe germline gDNA and normal gDNA 
from 22 healthy donors, to avoid the introduction of biases in variant calling due to the application of different 
deduplication protocols. Then, the deduped FASTQ sequencing reads were locally aligned to the hg19 version of the 
human genome assembly using the BWA v.0.6.2 software with the default setting, and sorted, indexed and assembled 
into a mpileup file using SAMtools v.1. The aligned read families were processed with mpileup using the parameters -A 
-d 10000000. For cases provided with paired germline gDNA, single nucleotide variations and indels were called in tumor 
gDNA vs germline gDNA, respectively, with the somatic function of VarScan2 using the parameters min-coverage 1 --
min-coverage-normal 1 --min-coverage-tumor 1 --min-var-freq 0--min-freq-for-hom 0.75 --somatic-p-value 0.05 --min-
avg-qual 20 --strand-filter 1 --validation 1. For cases lacking paired germline gDNA, single nucleotide variations and 
indels were called in tumor gDNA using the CNS function of VarScan2 using the parameters --min-coverage 0 --min-
readge 2 --min-avg-qual 20 --min-var-freq 0 --min-freq-for-hom 0.75 --p-value 0.05 --strand-filter 1 --output-vcf 1 --
variants 0. The variants called by VarScan 2 were annotated using the SeattleSeq Annotation 138 tool by using the default 
setting. Variants annotated as SNPs according to dbSNP 138 (with the exception of TP53 variants that were manually 
curated and scored as SNPs according to the IARC TP53 database), intronic variants mapping > 2 bp before the start or 
after the end of coding exons, and synonymous variants were then filtered out. The following strict post-processing filters 
were then applied to the remaining variants to further improve variant call confidence. To filter out variants below the 
base-pair resolution background frequencies in gDNA across the selector, for cases provided with paired germline gDNA, 
the Fisher's exact test was used to test whether the frequency of the variant called by VarScan 2 was significantly higher 
from that called in the corresponding paired germline gDNA, after adjusting for multiple comparisons by Bonferroni test 
[multiple comparisons corrected p threshold = 0.00000018761163, corresponding to alpha of 0.05/(66627 x 4 alleles per 
position]. Accordingly, variants represented in > 10 reads of the paired germline and/or variants with a somatic p value 
from VarScan2 > 0.00000018761163 were no further considered. To filter out systemic sequencing errors, a database 
containing all germline and normal gDNA background allele frequencies was assembled. Based on the assumption that 
all background allele fractions follow a normal distribution, for both cases provided with paired germline gDNA and 
cases lacking paired gDNA, a Z-test was employed to test whether a given variant in the tumor gDNA differed 
significantly in its frequency from typical germline or normal gDNA background at the same position in all the other 
germline and normal gDNA samples, after adjusting for multiple comparisons by Bonferroni test [multiple comparisons 
corrected p threshold = 0.00000018761163, corresponding to alpha of 0.05/(66627 x 4 alleles per position]. Variants that 
did not pass this filter were no further considered. Variant allele frequencies for the resulting candidate mutations and the 
background error rate were visualized using IGV.  
 
Statistical analysis 
Progression free survival (PFS) was the primary endpoint and was measured from date of treatment start to date of 
progression according to IWCLL-NCI guidelines (event), death (event) or last follow-up (censoring). Overall survival 
(OS) was measured from date of initial presentation to date of death from any cause (event) or last follow-up (censoring). 
Survival analysis was performed by Kaplan-Meier method and compared between strata using the Log-rank test. A false 
discovery rate approach was used to account for multiple testing, and adjusted p-values were calculated using the 
Bonferroni correction. A maximally selected rank statistic was used to determine the optimal cut-off for variant allele 
frequency (VAF) based on the Log-rank statistics. A cut-off of 3% of VAF was set for TP53 mutations and of 10% for 
all the other genes. The adjusted association between exposure variables and PFS was estimated by Cox regression. 
Internal validation of the multivariate analysis was performed using a bootstrap approach to estimate means and 
confidence intervals of hazard ratios, and percentage of selection for each variable in the model. The number of bootstrap 
samples used was 1000. Apoptosis assays were analyzed using the two-way ANOVA test. All statistical tests were two-
sided. Statistical significance was defined as p value < 0.05. The analysis was performed with the Statistical Package for 
the Social Sciences (SPSS) software v.24.0 (Chicago, IL), with R statistical package 3.1.2 and with GraphPad version 7 
(GraphPad Software Inc). 
 
 
 
SUPPLEMENTARY TABLES ON EXCEL FILE ONLY 
 
Table S1. Target region (Excel file)
 
Table S2. Target region with ≥1000X and ≥2000X coverage (Excel file)
 
Table S3. 11q deletion, 17p deletion and TP53 mutational status of tumor cell lines and primary CLL cells (Excel file)
 
Table S4. Primary cell lines divided into BIRC3/TP53 mutated or wild-type (WT). (Excel file)
 
Table S5. Somatic non-synonymous mutations discovered in tumor samples (Excel file)
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